Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25


CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity.

Li J, Piskol R, Ybarra R, Chen YJ, Li J, Slaga D, Hristopoulos M, Clark R, Modrusan Z, Totpal K, Junttila MR, Junttila TT.

Sci Transl Med. 2019 Sep 4;11(508). pii: eaax8861. doi: 10.1126/scitranslmed.aax8861.


Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3.

Slaga D, Ellerman D, Lombana TN, Vij R, Li J, Hristopoulos M, Clark R, Johnston J, Shelton A, Mai E, Gadkar K, Lo AA, Koerber JT, Totpal K, Prell R, Lee G, Spiess C, Junttila TT.

Sci Transl Med. 2018 Oct 17;10(463). pii: eaat5775. doi: 10.1126/scitranslmed.aat5775.


IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.

Li J, Ybarra R, Mak J, Herault A, De Almeida P, Arrazate A, Ziai J, Totpal K, Junttila MR, Walsh KB, Junttila TT.

Clin Cancer Res. 2018 Dec 15;24(24):6447-6458. doi: 10.1158/1078-0432.CCR-18-1139. Epub 2018 Jun 27.


Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.

Mandikian D, Takahashi N, Lo AA, Li J, Eastham-Anderson J, Slaga D, Ho J, Hristopoulos M, Clark R, Totpal K, Lin K, Joseph SB, Dennis MS, Prabhu S, Junttila TT, Boswell CA.

Mol Cancer Ther. 2018 Apr;17(4):776-785. doi: 10.1158/1535-7163.MCT-17-0657. Epub 2018 Jan 16.


Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing.

Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, Clark V, Hristopoulos M, Cook R, Slaga D, Nakamura R, McCarty L, Sukumaran S, Luis E, Ye Z, Wu TD, Sumiyoshi T, Danilenko D, Lee GY, Totpal K, Ellerman D, Hötzel I, James JR, Junttila TT.

Cancer Cell. 2017 Mar 13;31(3):383-395. doi: 10.1016/j.ccell.2017.02.001. Epub 2017 Mar 2.


Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells.

Dillon M, Yin Y, Zhou J, McCarty L, Ellerman D, Slaga D, Junttila TT, Han G, Sandoval W, Ovacik MA, Lin K, Hu Z, Shen A, Corn JE, Spiess C, Carter PJ.

MAbs. 2017 Feb/Mar;9(2):213-230. doi: 10.1080/19420862.2016.1267089. Epub 2016 Dec 8.


Afucosylated antibodies increase activation of FcγRIIIa-dependent signaling components to intensify processes promoting ADCC.

Liu SD, Chalouni C, Young JC, Junttila TT, Sliwkowski MX, Lowe JB.

Cancer Immunol Res. 2015 Feb;3(2):173-83. doi: 10.1158/2326-6066.CIR-14-0125. Epub 2014 Nov 11.


Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.

Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang BE, Li Y, Mathieu M, Li G, Young J, Luis E, Lewis Phillips G, Stefanich E, Spiess C, Polson A, Irving B, Scheer JM, Junttila MR, Dennis MS, Kelley R, Totpal K, Ebens A.

Cancer Res. 2014 Oct 1;74(19):5561-71. doi: 10.1158/0008-5472.CAN-13-3622-T. Epub 2014 Sep 16.


CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro.

Paatero I, Lassus H, Junttila TT, Kaskinen M, Bützow R, Elenius K.

Gynecol Oncol. 2013 Apr;129(1):179-87. doi: 10.1016/j.ygyno.2012.12.044. Epub 2013 Jan 9.


[Targeted cytotoxic drugs emerging for cancer therapy].

Junttila TT, Tanner M, Isola J.

Duodecim. 2011;127(4):343-9. Review. Finnish.


Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.

Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX.

Breast Cancer Res Treat. 2011 Jul;128(2):347-56. doi: 10.1007/s10549-010-1090-x. Epub 2010 Aug 21.


Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer.

Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, Pabonan O, Baginski T, Meng G, Totpal K, Kelley RF, Sliwkowski MX.

Cancer Res. 2010 Jun 1;70(11):4481-9. doi: 10.1158/0008-5472.CAN-09-3704. Epub 2010 May 18.


Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.

Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX.

Cancer Cell. 2009 May 5;15(5):429-40. doi: 10.1016/j.ccr.2009.03.020. Erratum in: Cancer Cell. 2011 Dec 13;20(6):818.


Intra- and extracellular signaling by endothelial neuregulin-1.

Iivanainen E, Paatero I, Heikkinen SM, Junttila TT, Cao R, Klint P, Jaakkola PM, Cao Y, Elenius K.

Exp Cell Res. 2007 Aug 1;313(13):2896-909. Epub 2007 Apr 18.


Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival.

Järvelä S, Helin H, Haapasalo J, Järvelä T, Junttila TT, Elenius K, Tanner M, Haapasalo H, Isola J.

Neuropathol Appl Neurobiol. 2006 Aug;32(4):441-50. Erratum in: Neuropathol Appl Neurobiol. 2006 Oct;32(5):568. Järvellä, S [corrected to Järvelä, Sally]; Järvellä, T [corrected to Järvelä, Timo].


Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.

Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K.

Clin Cancer Res. 2006 Jul 1;12(13):4103-11.


Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth.

Määttä JA, Sundvall M, Junttila TT, Peri L, Laine VJ, Isola J, Egeblad M, Elenius K.

Mol Biol Cell. 2006 Jan;17(1):67-79. Epub 2005 Oct 26.


DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation.

Mialon A, Sankinen M, Söderström H, Junttila TT, Holmström T, Koivusalo R, Papageorgiou AC, Johnson RS, Hietanen S, Elenius K, Westermarck J.

Mol Cell Biol. 2005 Jun;25(12):5040-51.


Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.

Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Härkönen P, Joensuu H, Isola J, Elenius K.

Cancer Res. 2005 Feb 15;65(4):1384-93.


Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J.

Ann Oncol. 2005 Feb;16(2):273-8.


ErbB4 is downregulated in renal cell carcinoma--a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family.

Thomasson M, Hedman H, Junttila TT, Elenius K, Ljungberg B, Henriksson R.

Acta Oncol. 2004;43(5):453-9.


Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor.

Iivanainen E, Nelimarkka L, Elenius V, Heikkinen SM, Junttila TT, Sihombing L, Sundvall M, Maatta JA, Laine VJ, Yla-Herttuala S, Higashiyama S, Alitalo K, Elenius K.

FASEB J. 2003 Sep;17(12):1609-21.


ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.

Gilbertson RJ, Bentley L, Hernan R, Junttila TT, Frank AJ, Haapasalo H, Connelly M, Wetmore C, Curran T, Elenius K, Ellison DW.

Clin Cancer Res. 2002 Oct;8(10):3054-64.


Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants.

Junttila TT, Sundvall M, Määttä JA, Elenius K.

Trends Cardiovasc Med. 2000 Oct;10(7):304-10. Review.


Supplemental Content

Loading ...
Support Center